Oyster Point Pharma (Oyster Point Pharma) Capex-to-Revenue : 0.00 (As of Sep. 2022)

View and export this data going back to 2019. Start your Free Trial

What is Oyster Point Pharma Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Oyster Point Pharma's Capital Expenditure for the three months ended in Sep. 2022 was $0.00 Mil. Its Revenue for the three months ended in Sep. 2022 was $5.59 Mil.

Hence, Oyster Point Pharma's Capex-to-Revenue for the three months ended in Sep. 2022 was 0.00.

Oyster Point Pharma Capex-to-Revenue Historical Data

The historical data trend for Oyster Point Pharma's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oyster Point Pharma Capex-to-Revenue Chart

Oyster Point Pharma Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Capex-to-Revenue

0.06

Oyster Point Pharma Quarterly Data
	Dec17	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Capex-to-Revenue	Get a 7-Day Free Trial														0.01	0.04	0.03	0.03	-

Competitive Comparison of Oyster Point Pharma's Capex-to-Revenue

For the Biotechnology subindustry, Oyster Point Pharma's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Oyster Point Pharma's Capex-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oyster Point Pharma's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Oyster Point Pharma's Capex-to-Revenue falls into.

Oyster Point Pharma Capex-to-Revenue Calculation

Oyster Point Pharma's Capex-to-Revenue for the fiscal year that ended in Dec. 2021 is calculated as

Capex-to-Revenue	=	- Capital Expenditure	/	Revenue
	=	- (-1.485)	/	24.539
	=	0.06

Oyster Point Pharma's Capex-to-Revenue for the quarter that ended in Sep. 2022 is calculated as

Capex-to-Revenue	=	- Capital Expenditure	/	Revenue
	=	- (0)	/	5.591
	=	0.00

Oyster Point Pharma (NAS:OYST) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.

Oyster Point Pharma Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Oyster Point Pharma's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Oyster Point Pharma (Oyster Point Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oyster Point Pharma Inc (NAS:OYST) » Definitions » Capex-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

202 Carnegie Center, Suite 109, Princeton, NJ, USA, 08540

Website

https://www.oysterpointrx.com

Oyster Point Pharma Inc is a biopharmaceutical company focused on the development of pharmaceutical therapies to treat ocular surface diseases. Its product candidate OC-01 is a nicotinic acetylcholine receptor (nAChR) agonist, is being developed as a nasal spray to treat the signs and symptoms of dry eye disease.

Executives

Ozawa Clare	director	ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Link William J Phd	director, 10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Versant Venture Capital Vi, L.p.	10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Donald J Santel	director	4362 24TH STREET, SAN FRANCISCO CA 94114
George Christopher Eliades	director	C/O OYSTER POINT PHARMA, INC., 202 CARNEGIE CENTER, SUITE 109, PRINCETON NJ 08540
Michael G Atieh	director	MERCK MEDCO MANAGED CARE INC, 100 SUMMIT AVE, MONTVALE NJ 07645
John Snisarenko	officer: Chief Commercial Officer	C/O ALIMERA SCIENCES, INC., 6120 WINDWARD PARKWAY, SUITE 290, ALPHARETTA GA 30005
Invopps Gp Iv, L.l.c.	director, 10 percent owner	126 EAST 56TH STREET, 20THFLOOR, NEW YORK NY 10022
Vida Ventures, Llc	10 percent owner	40 BROAD STREET, SUITE 201, BOSTON MA 02109
Kkr Healthcare Strategic Growth Fund L.p.	10 percent owner	C/O KOHLBERG KRAVIS ROBERTS & CO. L.P., 9 WEST 57TH STREET, SUITE 4200, NEW YORK NY 10019
Jeffrey Nau	director, officer: President and CEO	202 CARNEGIE CENTER, SUITE 106, PRINCETON NJ 08540
Daniel Lochner	officer: Chief Financial Officer	202 CARNEGIE CENTER, SUITE 106, PRINCETON NJ 08540
New Enterprise Associates 14, L.p.	10 percent owner	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Kkr Group Partnership L.p.	10 percent owner	C/O KOHLBERG KRAVIS ROBERTS & CO. L.P., 30 HUDSON YARDS, NEW YORK NY 10001
Invopps Iv Us, L.p.	director, 10 percent owner	126 EAST 56TH STREET, 20TH FLOOR, NEW YORK NY 10022